Related references
Note: Only part of the references are listed.Bioanalytical assay strategies for the development of antibody-drug conjugate biotherapeutics
Surinder Kaur et al.
BIOANALYSIS (2013)
Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody-drug conjugate in development for the treatment of HER2-positive cancer
Sandhya Girish et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2012)
Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
Sunil Verma et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Overcoming soluble target interference in an anti-therapeutic antibody screening assay for an antibody-drug conjugate therapeutic
Montserrat Carrasco-Triguero et al.
BIOANALYSIS (2012)
The potential for trastuzumab emtansine in human epidermal growth factor receptor 2 positive metastatic breast cancer: latest evidence and ongoing studies
Sara A. Hurvitz et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2012)
Trastuzumab Emtansine: A Unique Antibody-Drug Conjugate in Development for Human Epidermal Growth Factor Receptor 2-Positive Cancer
Patricia M. LoRusso et al.
CLINICAL CANCER RESEARCH (2011)
Trastuzumab emtansine in human epidermal growth factor receptor 2-positive breast cancer: a review
Jacob Mathew et al.
CURRENT OPINION IN ONCOLOGY (2011)
Trastuzumab emtansine: a novel antibody-drug conjugate for HER2-positive breast cancer
Howard A. Burris
EXPERT OPINION ON BIOLOGICAL THERAPY (2011)
Clinical immunogenicity specificity assessments: A platform evaluation
Kun Peng et al.
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS (2011)
Immunogenicity of Therapeutic Proteins: The Use of Animal Models
Vera Brinks et al.
PHARMACEUTICAL RESEARCH (2011)
Phase I Study of Trastuzumab-DM1, an HER2 Antibody-Drug Conjugate, Given Every 3 Weeks to Patients With HER2-Positive Metastatic Breast Cancer
Ian E. Krop et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
A novel homogeneous Biotin-digoxigenin based assay for the detection of human anti-therapeutic antibodies in autoimmune serum
Zhihua Julia Qiu et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2010)
Rationale and development of multispecific antibody drugs
Jijie Gu et al.
Expert Review of Clinical Pharmacology (2010)
Safety of Therapeutic Monoclonal Antibodies
Ronald Niebecker et al.
CURRENT DRUG SAFETY (2010)
Antibody-drug conjugates for cancer therapy
Paul J. Carter et al.
CANCER JOURNAL (2008)
Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody-Cytotoxic Drug Conjugate
Gail D. Lewis Phillips et al.
CANCER RESEARCH (2008)
Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology products
Eugen Koren et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2008)
Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products
Gopi Shankar et al.
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS (2008)
Cetuximab-induced anaphylaxis and IgE specific for galactose-α-1,3-galactose
Christine H. Chung et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Nanocarriers as an emerging platform for cancer therapy
Dan Peer et al.
NATURE NANOTECHNOLOGY (2007)
Scientific and regulatory considerations on the immunogenicity of biologics
Gopi Shankar et al.
TRENDS IN BIOTECHNOLOGY (2006)
Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products
AR Mire-Sluis et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2004)
Share Paper
